March 12, 2008 - Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has signed an exclusive license agreement with
Makoto Life Sciences, Inc., of Cambridge, Massachusetts.
Under this agreement, MTI has licensed to Makoto its lead series of high potency activators of AMP-activated protein kinase (AMPK), a well validated drug target for the treatment of Type-2 diabetes. As part of the license, MTI will transfer all assets related to its MT-39 series of indirect AMPK activators, including all materials, research notes, synthetic routes, and the structures of over 40 compounds. MTI will advise Makoto on the continuing development of the MT-39 series...
March 12, 2008 - Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has signed an exclusive license agreement with Makoto Life Sciences, Inc., of Cambridge, Massachusetts.
Under this agreement, MTI has licensed to Makoto its lead series of high potency activators of AMP-activated protein kinase (AMPK), a well validated drug target for the treatment of Type-2 diabetes. As part of the license, MTI will transfer all assets related to its MT-39 series of indirect AMPK activators, including all materials, research notes, synthetic routes, and the structures of over 40 compounds. MTI will advise Makoto on the continuing development of the MT-39 series...
